IP Library Granted Patent US 11,529,396
Granted Patent B2
US 11,529,396 · App. 15/502,522 · Granted Dec 20, 2022

Telomerase reverse transcriptase-based therapies

Inventors: Maria Bobadilla (Rosenau, FR); Ivan Formentini (Basel, CH); Maria Antonia Blasco Marhuenda (Madrid, ES); Christian Baer (Madrid, ES); Fàtima Bosch I Tubert (Bellaterra, ES)
Assignees: FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DL'INVESTIGACIONES ONCOLÓGICAS CARLOS III (F.S.P. CNIO); UNIVERSITAT AUTÓNOMA DE BARCELONA
A61K38/45A01K67/0271A01K67/0276A61K48/005A61K48/0058A61K48/0066C12N9/1276C12Y207/07049A01K2207/12A01K2217/075A01K2217/206A01K2227/105A01K2267/03A01K2267/0381C12N2750/14145
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,529,396
App. No.
15/502,522
Granted
Dec 20, 2022
Kind
B2
Abstract

The invention provides compositions and methods useful for the treatment and prevention of conditions associated with short telomere length.

Claims (8)

1. A method of treating a condition associated with aplastic anemia, the method comprising:

administering to a subject in need thereof an adeno-associated virus-based vector comprising at least a capsid and a nucleic acid encoding telomerase reverse transcriptase (TERT) operably linked to a regulatory sequence that drives the expression of the encoded TERT, wherein the method results in transduction of hematopoietic stem cells.

2. The method of claim 1 , wherein TERT is encoded by a nucleic acid sequence comprising the sequence of SEQ ID NO: 1 or SEQ ID NO: 3.

3. The method of claim 1 , wherein TERT comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 4.

4. The method of claim 1 , wherein the capsid is derived from serotype 9 adeno-associated virus (AAV9).

5. The method of claim 4 , wherein nucleic acid is packaged in the AAV9 capsid and is flanked at both ends by the internal terminal repeats of the serotype 2 adeno-associated virus.

6. The method of claim 1 , wherein the regulatory sequence is a constitutive promoter.

7. The method of claim 6 , wherein the constitutive promoter is the cytomegalovirus (CMV) promoter.

Assignments (2)
CHANGE OF NAME Recorded Jul 2, 2021
From: FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS III
To: FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (F.S.P. CNIO)
Reel/Frame 056740/0491 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2017
From: BOBADILLA, MARIA; FORMENTINI, IVAN; BLASCO MARHUENDA, MARIA ANTONIA; BAER, CHRISTIAN; BOSCH I TUBERT, FÀTIMA
To: FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCÓLOGICAS CARLOSIII; UNIVERSITAT AUTÒNOMA DE BARCELONA
Reel/Frame 041854/0001 →
Priority Claims (1)
EP 14382312 · Aug 8, 2014 · regional
Continuity (1)
Related Publication 20170232075A1 · Aug 17, 2017